$ADMA
ADMA BIOLOGICS, INC. Stock $adma

$adma Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000119380521000657 Filed on May 12, 2021

Income Statement

Concept	2021 Q1	2020 Q1	2019 Q4
Revenue	$16.05M	$10.20M	$12.04M
YoY Change	57.34%	188.94%	196.55%
Cost Of Revenue	$17.77M	$16.83M	$11.69M
YoY Change	5.59%	78.84%	4.94%
Gross Profit	-$1.722M	-$6.629M	$350.0K
YoY Change	-74.03%	12.75%	-104.94%
Gross Profit Margin	-10.73%	-65.0%	2.91%
Selling, General & Admin	$10.03M	$8.430M	$7.500M
YoY Change	19.03%	34.88%	-20.21%
% of Gross Profit			2142.86%
Research & Development	$987.6K	$1.529M	$460.0K
YoY Change	-35.39%	75.72%	-428.57%
% of Gross Profit			131.43%
Depreciation & Amortization	$1.100M	$600.0K	$830.0K
YoY Change	83.33%	-25.93%	-10.75%
% of Gross Profit			237.14%
Operating Expenses	$13.44M	$26.97M	$8.170M
YoY Change	-50.16%	267.93%	-13.64%
Operating Profit	-$15.16M	-$16.77M	-$7.820M
YoY Change	-9.57%	26.95%	-52.75%
Interest Expense	$3.196M	$2.717M	-$2.550M
YoY Change	17.62%	-292.7%	84.78%
% of Operating Profit
Other Income/Expense, Net	-$3.216M	-$2.475M	-$190.0K
YoY Change	29.9%	24654.44%	72.73%
Pretax Income	-$18.38M	-$19.25M	-$10.56M
YoY Change	-4.52%	47.28%	-41.46%
Income Tax
% Of Pretax Income
Net Earnings	-$18.38M	-$19.25M	-$10.56M
YoY Change	-4.5%	47.27%	-41.46%
Net Earnings / Revenue	-114.53%	-188.68%	-87.71%
Basic Earnings Per Share	-$0.16
Diluted Earnings Per Share	-$0.16	-$260.9K	-$177.9K
COMMON SHARES
Basic Shares Outstanding	115.7M
Diluted Shares Outstanding	115.7M

Balance Sheet

Concept	2021 Q1	2020 Q1	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$62.00M	$101.2M	$26.80M
YoY Change	-38.74%	513.33%	17.54%
Cash & Equivalents	$61.97M	$101.2M	$26.75M
Short-Term Investments
Other Short-Term Assets	$5.800M	$4.900M	$2.500M
YoY Change	18.37%	145.0%	38.89%
Inventory	$94.15M	$52.30M	$53.06M
Prepaid Expenses
Receivables	$15.40M	$7.100M	$3.470M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$177.3M	$165.5M	$85.82M
YoY Change	7.13%	332.11%	92.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$44.18M	$35.10M	$31.74M
YoY Change	25.86%	18.18%	5.45%
Goodwill			$3.530M
YoY Change
Intangibles			$3.159M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.200M	$3.500M	$2.800M
YoY Change	-37.14%	25.0%	-58.21%
Total Long-Term Assets	$58.37M	$45.00M	$41.27M
YoY Change	29.7%	13.07%	-7.05%
TOTAL ASSETS
Total Short-Term Assets	$177.3M	$165.5M	$85.82M
Total Long-Term Assets	$58.37M	$45.00M	$41.27M
Total Assets	$235.7M	$210.5M	$127.1M
YoY Change	11.96%	169.53%	42.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.20M	$9.200M	$9.175M
YoY Change	32.61%	67.27%	55.5%
Accrued Expenses	$8.100M	$4.600M	$4.481M
YoY Change	76.09%	70.37%	24.48%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$21.20M	$13.90M	$14.03M
YoY Change	52.52%	67.47%	46.12%
LONG-TERM LIABILITIES
Long-Term Debt	$93.40M	$96.10M	$83.20M
YoY Change	-2.81%	72.22%	88.66%
Other Long-Term Liabilities	$41.97K	$4.200M	$106.6K
YoY Change	-99.0%	5.0%	-99.31%
Total Long-Term Liabilities	$41.97K	$100.3M	$106.6K
YoY Change	-99.96%	67.73%	-99.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.20M	$13.90M	$14.03M
Total Long-Term Liabilities	$41.97K	$100.3M	$106.6K
Total Liabilities	$123.2M	$114.2M	$100.9M
YoY Change	7.85%	67.69%	46.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$358.8M		-$264.7M
YoY Change
Common Stock	$12.30K		$5.932K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$112.5M	$96.34M	$26.19M
YoY Change
Total Liabilities & Shareholders Equity	$235.7M	$210.5M	$127.1M
YoY Change	11.96%	169.53%	42.96%

Cashflow Statement

Concept	2021 Q1	2020 Q1	2019 Q4
OPERATING ACTIVITIES
Net Income	-$18.38M	-$19.25M	-$10.56M
YoY Change	-4.5%	47.27%	-41.46%
Depreciation, Depletion And Amortization	$1.100M	$600.0K	$830.0K
YoY Change	83.33%	-25.93%	-10.75%
Cash From Operating Activities	-$33.23M	-$24.65M	-$19.65M
YoY Change	34.82%	72.48%	4.58%
INVESTING ACTIVITIES
Capital Expenditures	$2.571M	$2.075M	-$1.590M
YoY Change	23.92%	-1986.25%	93.9%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$2.571M	-$2.073M	-$1.590M
YoY Change	24.04%	1784.43%	93.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$41.91M	$12.30M
YoY Change	240.75%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$41.84M	$101.2M	-10.00K
YoY Change	-58.65%	2321.13%
NET CHANGE
Cash From Operating Activities	-$33.23M	-$24.65M	-19.65M
Cash From Investing Activities	-$2.571M	-$2.073M	-1.590M
Cash From Financing Activities	$41.84M	$101.2M	-10.00K
Net Change In Cash	$6.045M	$74.48M	-21.25M
YoY Change	-91.88%	-828.8%	8.36%
FREE CASH FLOW
Cash From Operating Activities	-$33.23M	-$24.65M	-$19.65M
Capital Expenditures	$2.571M	$2.075M	-$1.590M
Free Cash Flow	-$35.80M	-$26.72M	-$18.06M
YoY Change	33.97%	88.45%	0.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	128189628	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55921152	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13237290	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	81535599	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3046466	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	153740507	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41593090	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2444121	USD
CY2020Q4	us-gaap	Goodwill Goodwill	3529509	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4259191	USD
CY2020Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2106976	USD
CY2020Q4	us-gaap	Assets Assets	207673394	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11073708	USD
CY2021Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	8592142	USD
CY2020Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	8365143	USD
CY2020Q1	us-gaap	Cost Of Revenue CostOfRevenue	16829226	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	987649	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1528738	USD
CY2021Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2242343	USD
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	142834	USD
CY2020Q4	adma	Lease Obligations Current LeaseObligationsCurrent	365682	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19947367	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	92968866	USD
CY2020Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2118698	USD
CY2021Q1	adma	Lease Obligations Noncurrent LeaseObligationsNoncurrent	6419589	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	41965	USD
CY2021Q1	us-gaap	Liabilities Liabilities	123162942	USD
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	123044981	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	104902888	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	12304	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	471336826	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-358845044	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	112504086	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	235667028	USD
CY2021Q1	adma	Product Revenue ProductRevenue	16012910	USD
CY2020Q1	adma	Product Revenue ProductRevenue	10164036	USD
CY2021Q1	adma	License Revenue LicenseRevenue	35708	USD
CY2020Q1	adma	License Revenue LicenseRevenue	35708	USD
CY2021Q1	us-gaap	Revenues Revenues	16048618	USD
CY2020Q1	us-gaap	Revenues Revenues	10199744	USD
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	17770122	USD
CY2020Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	500644	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	178838	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	178838	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10033915	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7932084	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	31212867	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	26969530	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15164249	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16769786	USD
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	443794	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	781397	USD
CY2021Q1	adma	Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes And Retired Amount VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount	-59311	USD
CY2021Q1	adma	Issuance Of Common Stock Net Of Offering Expenses Amount IssuanceOfCommonStockNetOfOfferingExpensesAmount	41912515	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	22059	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	248068	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	3195750	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	2717091	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-42001	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6421	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3215692	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2475444	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-18379941	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19245230	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	115661937	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	73781507	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	88249426	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-18379941	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	112504086	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	26193149	USD
CY2020Q1	adma	Stock Based Compensation StockBasedCompensation	676548	USD
CY2020Q1	adma	Issuance Of Common Stock Net Of Offering Expenses Amount IssuanceOfCommonStockNetOfOfferingExpensesAmount	88704039	USD
CY2020Q1	adma	Exercise Of Stock Options Amount ExerciseOfStockOptionsAmount	7177	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19245230	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	96335683	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-18379941	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19245230	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1229628	USD
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	788838	USD
CY2021Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	781	USD
CY2020Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	976	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	781397	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	676548	USD
CY2020Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	429711	USD
CY2021Q1	adma	Amortization Of License Revenue AmortizationOfLicenseRevenue	-35708	USD
CY2020Q1	adma	Amortization Of License Revenue AmortizationOfLicenseRevenue	-35708	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2124740	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3637915	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-12610601	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	775932	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2756142	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2321751	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	19718	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-79532	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1079144	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-22356	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-843043	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1930591	USD
CY2021Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-33413	USD
CY2020Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-45882	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33229126	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24646960	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2571161	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2074876	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2571161	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2072876	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	41912515	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	88704039	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7177	USD
CY2021Q1	adma	Taxes Paid On Vested Restricted Stock Units TaxesPaidOnVestedRestrictedStockUnits	-59311	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	12500000	USD
CY2021Q1	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	8360	USD
CY2020Q1	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	7816	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41844844	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	101203400	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6044557	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	74483564	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55921152	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26752135	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61965709	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	101235699	USD
CY2021Q1	adma	Working Capital WorkingCapital	156100000	USD
CY2021Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	62000000.0	USD
CY2021Q1	adma	Cumulative Loss CumulativeLoss	358800000	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards granted under the Company’s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company’s deferred tax assets.</p>
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13362319	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9225014	shares
CY2021Q1	us-gaap	Goodwill Gross GoodwillGross	3500000	USD
CY2021Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	38411316	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	32044393	USD
CY2021Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	34560999	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	30293288	USD
CY2021Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	21173885	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	19197918	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	94146200	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	81535599	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6084024	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3818741	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2265283	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6084024	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3639903	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2444121	USD
CY2021Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	200000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	536514	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	715352	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	715352	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	298065	USD
CY2021Q1	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P30Y
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1100000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	207262	USD
CY2021Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8592142	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8365143	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	54079627	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	50457032	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9904014	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8863942	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44175613	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41593090	USD
CY2021Q1	adma	Accrued Rebates AccruedRebates	3042550	USD
CY2020Q4	adma	Accrued Rebates AccruedRebates	2604245	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1503680	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	828120	USD
CY2021Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1335383	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	734972	USD
CY2021Q1	us-gaap	Liability Premium Deficiency Testing On Long Duration Contract Amount LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount	1168270	USD
CY2020Q4	us-gaap	Liability Premium Deficiency Testing On Long Duration Contract Amount LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount	779660	USD
CY2021Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	773721	USD
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	3210884	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	768538	USD
CY2021Q1	us-gaap	Notes Payable NotesPayable	100000000	USD
CY2020Q4	us-gaap	Notes Payable NotesPayable	100000000	USD
CY2021Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	-6587340	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	-7031134	USD
CY2021Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	93412660	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	92968866	USD
CY2021Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.137	pure
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	123044981	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	104902888	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	17080606	shares
CY2021Q1	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	9874413	shares
CY2020Q1	adma	Underwritten Public Offering UnderwrittenPublicOffering	23500000	shares
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	82300000	USD
CY2020Q1	adma	Underwritten Public Offering UnderwrittenPublicOffering	3525000	shares
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12300000	USD
CY2020Q1	adma	Net Proceeds From The Issuance Of Common Stock NetProceedsFromTheIssuanceOfCommonStock	88700000	USD
CY2021Q1	adma	Weighted Average Exercise Price Of Outstanding Warrants WeightedAverageExercisePriceOfOutstandingWarrants	2.82
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.69	pure
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.62	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1441050	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1158900	shares
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	781397	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	676548	USD
CY2021Q1	adma	Credit Facility Percentage CreditFacilityPercentage	0.10	pure
CY2021Q1	adma	Public Offering Description PublicOfferingDescription	(i) Perceptive Advisors, a principal stockholder of ADMA, purchased 4,563,700 shares of common stock through one of its affiliates, (ii) Dr. Grossman purchased 22,857 shares of common stock directly and 22,857 shares indirectly through an entity he controls, (iii) Lawrence P. Guiheen, a director of the Company, purchased 20,000 shares of common stock, (iv) Mr. Grossman purchased 28,571 shares of common stock directly and 57,143 shares indirectly through an entity he controls, (v) Brian Lenz, the Company’s Executive Vice President and Chief Financial Officer, purchased 7,142 shares of common stock, and (vi) Dr. James Mond, the Company’s Chief Scientific Officer and Chief Medical Officer, purchased 4,285 shares of common stock, all at the public offering price of $3.50 per share
CY2021Q1	adma	Plasma Supply Agreement Term PlasmaSupplyAgreementTerm	P10Y
CY2021Q1	adma	Purchase Of Raw Material PurchaseOfRawMaterial	12700000	USD
CY2021Q1	adma	Purchase Percentage From Inventory PurchasePercentageFromInventory	0.72	pure
CY2020Q1	adma	Purchase Of Raw Material PurchaseOfRawMaterial	2000000.0	USD
CY2020Q1	adma	Purchase Percentage From Inventory PurchasePercentageFromInventory	0.46	pure
CY2021Q1	adma	Incremental Borrowing Rate IncrementalBorrowingRate	0.13	pure
CY2021Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000	USD
CY2020Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
CY2021Q1	adma	Cash Payments For Lease CashPaymentsForLease	200000	USD
CY2020Q1	adma	Cash Payments For Lease CashPaymentsForLease	100000	USD
CY2021Q1	adma	Right To Use Assets And Corresponding Lease Liabilities RightToUseAssetsAndCorrespondingLeaseLiabilities	2100000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	6700000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4700000	USD
CY2021Q1	adma	Weighted Average Remaining Term WeightedAverageRemainingTerm	P9Y3M18D
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	852315	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1374513	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1386375	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1257300	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1261052	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four And Five Years OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears	990732	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	4718836	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	11841123	USD
CY2021Q1	adma	Interest Portion Of Minimum Lease Payments InterestPortionOfMinimumLeasePayments	-5103624	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	-317910	USD
CY2021Q1	adma	Operating Lease Liability Total OperatingLeaseLiabilityTotal	6419589	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	2751956	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	2017866	USD
CY2021Q1	adma	Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities	1797249	USD
CY2020Q1	adma	Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities	2340337	USD
CY2021Q1	adma	Right To Use Assets In Exchange For Lease Obligations RightToUseAssetsInExchangeForLeaseObligations	2073627	USD
CY2020Q1	adma	Right To Use Assets In Exchange For Lease Obligations RightToUseAssetsInExchangeForLeaseObligations	545630	USD

Files In Submission

Name	View Source	Status
0001193805-21-000657-index-headers.html	Edgar Link	pending
0001193805-21-000657-index.html	Edgar Link	pending
0001193805-21-000657.txt	Edgar Link	pending
0001193805-21-000657-xbrl.zip	Edgar Link	pending
adma-20210331.xsd	Edgar Link	pending
adma-20210331_cal.xml	Edgar Link	unprocessable
adma-20210331_def.xml	Edgar Link	unprocessable
adma-20210331_lab.xml	Edgar Link	unprocessable
adma-20210331_pre.xml	Edgar Link	unprocessable
adma_10q.htm	Edgar Link	pending
adma_10q_htm.xml	Edgar Link	completed
adma_ex101.htm	Edgar Link	pending
adma_ex311.htm	Edgar Link	pending
adma_ex312.htm	Edgar Link	pending
adma_ex321.htm	Edgar Link	pending
adma_ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADMA
ADMA BIOLOGICS, INC. Stock $adma

2021 Q1 Form 10-Q Financial Statement

#000119380521000657 Filed on May 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADMA ADMA BIOLOGICS, INC. Stock $adma

2021 Q1 Form 10-Q Financial Statement

#000119380521000657 Filed on May 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADMA
ADMA BIOLOGICS, INC. Stock $adma